Centre Europeen De Recherches Mauvernay

Centre Europeen De Recherches Mauvernay 'cerm'

Centre European De Recherches Mauvernay

Societe Anonyme Dite: Centre Europen De Recherches Mauvernay (c.e.r.m.)

Jacques Moleyre

Andre J Monteil

Norbert Busch

Jacques A Simond

Roland Yves Mauvernay

Roland-Yves Mauvernay

Norbert Bush

Jacques Simons

Substituted methyl-2-[(dimethylamino-3')propylidene]-4-dihydro-9,10-benzo-[4,5]cyclohe pta[1,2-b]-furan compounds are described which are useful in the treatment of depressive syndromes and which may be obtained by cyclization from substituted derivatives of furan.

Anti-depressive

The invention relates to novel 6-aryloxy-2-oxo-1-aza-4-(or thia)-spiro[4,5]decane compounds. These compounds are represented by the formula: ##STR1## in which A stands for an oxygen or sulfur heteroatom; R.sub.1 and R.sub.2 are each H, lower alkyl or aryl such as phenyl; X is H, a halogen atom such as chlorine or fluorine or a lower alkyl. Compounds according to the invention are useful as stimulating agents for vigilance, as psycho-stimulators and genesic stimulators.

Certain 6-aryloxy-2-oxo-1-aza-4-thia-spiro[4,5]decanes

2-(2-Hydroxyethyl)tetrahydro-1,4-oxazines and quaternary salts thereof having the formula: ##STR1## WHEREIN Ar and Ar.sub.1 are the same or different and are unsubstituted and substituted aryl, said substituent being a halogen atom, R represents a lower alkyl group having from 1 to 4 carbon atoms, R.sub.1 is zero when X.sup.(-) is zero or is an alkyl group of from 1 to 4 carbon atoms which is the same or different from R, as defined above, and X.sup.(-) is zero when R.sub.1 is zero or is selected from the group consisting of Cl.sup.(-), Br.sup.(-), I.sup.(-) and CH.sub.3 SO.sub.4.sup.(-) when R.sub.1 is lower alkyl, as defined above, is described. These compounds are useful for treating spasmodic syndromes.

Substituted 2-(2-hydroxyethyl)tetrahydro-1,4 oxazines and quaternary

Compounds of the formula: ##STR1## wherein R is a lower alkyl group, X is oxygen or the group --(CH.sub.2).sub.n -- where n is 0 or 1, having bronchospasmolytic activity, are described.

Pharmaceutically active compounds and the preparation thereof

Compounds of the formula ##STR1## and pharmaceutically acceptable acid salts thereof, wherein X is hydrogen, halogen or methoxy, n is zero, Y is halogen and the ethyl piperazaine moiety is attached to the 2- or 4- position of the piperidine ring, is described. These compounds have anti-spasmolytic and antitussive activity.

1-Benzoyl-2 or 4 [2-(4-phenyl-piperazino)-ethyl]-piperidines

This invention relates to a new group of substituted cysteines having the general formula: ##STR1## in which: Ar is an aromatic or heteromonocyclic group, such as 2-thienyl or phenyl, which may be substituted by a halogen atom or by a lower alkyl or alkoxy group, and R is a hydrogen atom or a lower alkyl group. These compounds are of use in human therapeutics as liquifiers for bronchal secretions in complaints of the respiratory passage and, in particular, in chronic bronchitis. The invention also relates to a method of preparing these compounds and to the application of these compounds, particularly in human therapeutics.

Substituted cysteines

Novel compounds, certain 3-aryloxy-2-hydroxy-cyclohexyl-amines, having vable pharmacological properties e.g. antidepressant activity are described together with a process for their preparation, pharmaceutical compositions thereof and a method of treatment involving their use.

Substituted cyclohexanes, pharmaceutical compositions containing them

Ethers of n-propanolamine, preparation thereof and their use in treatment of cardiovascular conditions.

Ethers of n-propanol amine

Tetra-substituted ethylenes having the general formula ##EQU1## in which R is selected from the group consisting of alkyl radicals containing 1 to 4 carbon atoms and ##SPC1## AND A is selected from the group consisting of ##EQU2## and salts thereof with pharmacologically acceptable acids are useful as anti-inflammatory agents.

Growing community of inventors

Mozac, France

Jacques Moleyre